Annovis Bio Inc (ANVS)
8.70
+0.34
(+4.07%)
USD |
NYSE |
May 15, 16:00
8.70
0.00 (0.00%)
After-Hours: 16:27
Annovis Bio Enterprise Value: 90.26M for May 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 90.26M |
| May 13, 2024 | 73.39M |
| May 10, 2024 | 63.11M |
| May 09, 2024 | 64.23M |
| May 08, 2024 | 49.99M |
| May 07, 2024 | 55.83M |
| May 06, 2024 | 56.27M |
| May 03, 2024 | 53.95M |
| May 02, 2024 | 56.93M |
| May 01, 2024 | 64.20M |
| April 30, 2024 | 58.25M |
| April 29, 2024 | 77.10M |
| April 26, 2024 | 195.36M |
| April 25, 2024 | 146.76M |
| April 24, 2024 | 137.15M |
| April 23, 2024 | 127.68M |
| April 22, 2024 | 123.38M |
| April 19, 2024 | 107.64M |
| April 18, 2024 | 105.32M |
| April 17, 2024 | 95.85M |
| April 16, 2024 | 107.86M |
| April 15, 2024 | 118.98M |
| April 12, 2024 | 124.92M |
| April 11, 2024 | 131.20M |
| April 10, 2024 | 126.25M |
| Date | Value |
|---|---|
| April 09, 2024 | 123.38M |
| April 08, 2024 | 123.05M |
| April 05, 2024 | 119.09M |
| April 04, 2024 | 118.43M |
| April 03, 2024 | 121.18M |
| April 02, 2024 | 119.97M |
| April 01, 2024 | 128.56M |
| March 28, 2024 | 125.28M |
| March 27, 2024 | 126.71M |
| March 26, 2024 | 123.96M |
| March 25, 2024 | 125.28M |
| March 22, 2024 | 118.78M |
| March 21, 2024 | 120.76M |
| March 20, 2024 | 112.96M |
| March 19, 2024 | 89.64M |
| March 18, 2024 | 93.59M |
| March 15, 2024 | 90.42M |
| March 14, 2024 | 88.62M |
| March 13, 2024 | 90.42M |
| March 12, 2024 | 93.06M |
| March 11, 2024 | 89.57M |
| March 08, 2024 | 89.15M |
| March 07, 2024 | 87.35M |
| March 06, 2024 | 93.17M |
| March 05, 2024 | 90.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.993M
Minimum
Apr 02 2020
929.53M
Maximum
Jul 13 2021
114.57M
Average
77.42M
Median
Jul 12 2022
Enterprise Value Benchmarks
| Ligand Pharmaceuticals Inc | 1.222B |
| ANI Pharmaceuticals Inc | 1.456B |
| FibroGen Inc | 53.96M |
| Cerus Corp | 390.74M |
| Stereotaxis Inc | 157.41M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.067M |
| Total Expenses (Quarterly) | 7.810M |
| EPS Diluted (Quarterly) | -0.10 |
| Earnings Yield | -58.97% |